 This is a two phase, 24-week research study in which participants who remain symptomatic at the end of one phase 6 weeks enter into the next phase. In phase I, all participants receive 60mgday of duloxetine Cymbalta for 6 weeks. Participants who continue to have anxiety symptoms will enter the 18-week Phase II, in which they continue taking 60 mgday of duloxetine and they will also be randomly assigned by chance, like a flip of a coin to receive either an additional 60mgday of duloxetine or placebo contains no active medication. 